LCC
ABBV icon

Lincoln Capital Corp’s AbbVie ABBV Stock Holding History

Lincoln Capital Corp’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$478K Buy
+1,900
New +$409K 0.16% 70
2024
Q2 		– Sell
-1,585
Closed -$289K – 83
2024
Q1 		$289K Buy
1,585
+110
+7% +$19K 0.13% 58
2023
Q4 		$229K Sell
1,475
-15
-1% -$2.19K 0.11% 69
2023
Q3 		$222K Sell
1,490
-310
-17% -$45.5K 0.12% 67
2023
Q2 		$243K Sell
1,800
-137
-7% -$20.1K 0.12% 63
2023
Q1 		$309K Sell
1,937
-996
-34% -$152K 0.18% 49
2022
Q4 		$474K Sell
2,933
-600
-17% -$92K 0.29% 41
2022
Q3 		$474K Sell
3,533
-563
-14% -$80.8K 0.32% 41
2022
Q2 		$627K Buy
4,096
+740
+22% +$113K 0.4% 40
2022
Q1 		$544K Buy
3,356
+456
+16% +$66.2K 0.28% 44
2021
Q4 		$393K Hold
2,900
– – 0.19% 50
2021
Q3 		$313K Hold
2,900
– – 0.17% 48
2021
Q2 		$327K Sell
2,900
-436
-13% -$49.1K 0.19% 43
2021
Q1 		$361K Hold
3,336
– – 0.23% 42
2020
Q4 		$357K Hold
3,336
– – 0.23% 40
2020
Q3 		$292K Hold
3,336
– – 0.21% 42
2020
Q2 		$328K Buy
+3,336
New +$294K 0.26% 40
2020
Q1 		– Sell
-6,279
Closed -$556K – 45
2019
Q4 		$556K Sell
6,279
-895
-12% -$74.3K 0.41% 38
2019
Q3 		$543K Sell
7,174
-168
-2% -$11.5K 0.46% 37
2019
Q2 		$534K Sell
7,342
-703
-9% -$55.3K 0.47% 40
2019
Q1 		$648K Sell
8,045
-2,008
-20% -$164K 0.59% 35
2018
Q4 		$927K Sell
10,053
-463
-4% -$40.7K 0.85% 35
2018
Q3 		$995K Sell
10,516
-22,703
-68% -$2.15M 0.83% 31
2018
Q2 		$3.08M Sell
33,219
-1,490
-4% -$146K 2.86% 16
2018
Q1 		$3.29M Sell
34,709
-11,074
-24% -$1.22M 3.05% 14
2017
Q4 		$4.43M Sell
45,783
-3,578
-7% -$337K 3.78% 9
2017
Q3 		$4.39M Sell
49,361
-966
-2% -$73.5K 3.92% 9
2017
Q2 		$3.65M Buy
50,327
+475
+1% +$31.9K 3.23% 15
2017
Q1 		$3.25M Sell
49,852
-5,251
-10% -$330K 2.9% 13
2016
Q4 		$3.46M Buy
+55,103
New +$3.36M 3.33% 9

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

Lincoln Capital Corp's ABBV Position: Q2 2026 in Review

Lincoln Capital Corp opened a new position in AbbVie (ABBV) in Q2 2026: 1,900 shares worth $478K. The stake represents 0.16% of the portfolio and ranks #70 among its holdings. This is a return to the name: Lincoln Capital Corp previously reported a position in ABBV as recently as Q1 2024.

Lincoln Capital Corp first reported a position in ABBV in Q4 2016 and has held it in 30 quarters since. The position peaked at $4.43M in Q4 2017. 1,316 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Lincoln Capital Corp held 1,900 shares of AbbVie worth $478K as of Q2 2026.
  • AbbVie was a new Lincoln Capital Corp position in Q2 2026.
  • AbbVie made up 0.16% of Lincoln Capital Corp's portfolio in Q2 2026, its #70 holding.
  • Lincoln Capital Corp first reported a position in AbbVie in Q4 2016 and has held it in 30 quarters since.
  • Lincoln Capital Corp's AbbVie position peaked at $4.43M in Q4 2017.
  • 1,316 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Lincoln Capital Corp's 13F filing for Q2 2026, filed 16 Jul 2026.